A 2018 critique of 16 experiments of cannabis-centered medicines for neuropathic discomfort, the majority of which analyzed a cannabinoid preparation referred to as nabiximols (brand name identify Sativex; a mouth spray that contains equally THC and CBD which is accepted in certain international loc